José M. Azevedo Pereira

PhD (2001) in Pharmacy (Microbiology), Universidade de Lisboa

Habilitation (2015) in Pharmacy (Microbiology), Universidade de Lisboa

Assistant Professor, Microbiology and Immunology, Faculdade de Farmácia, Universidade de Lisboa

Faculdade de Farmácia, Universidade de Lisboa — Av. Prof. Gama Pinto, 1649-003 Lisboa, Portugal

T (+351) 217 946 400
F (+351) 217 986 055
Researcher ID B-3404-2008
Group Researcher ID B-4239-2014
Scopus Author ID 6506539639

Research Interests

Our main goal is to study the interactions of HIV with target cells and the way those interactions are important in pathogenic mechanisms of HIV infection. We focus on:

  • The interaction of primary HIV-2 with dendritic cells and macrophages trying to find reasons for the lower virulence of HIV-2 infection.
  • To decipher the contribution of extracellular vesicular membranes in the dissemination of HIV infection in central nervous system (CNS), in HIV-associated neuroinflammation, and as carriers of microRNAs that are important in neuronal degenerescence.

Selected Publications

Azevedo-Pereira JM*, Santos-Costa Q. HIV Interaction With Human Host: HIV-2 As a Model of a Less Virulent Infection. AIDS Reviews 2016; 18: 44-53.

Piedade D, Azevedo-Pereira JM*. MicroRNAs, HIV and HCV: a complex relation towards pathology. Reviews in Medical Virology 2016; 26: 197-215.

Santos-Costa Q, Lopes MM, Calado M, Azevedo-Pereira JM.* HIV-2 interaction with cell coreceptors: Amino acids within the V1/V2 region of viral envelope are determinant for CCR8, CCR5 and CXCR4 usage. Retrovirology 2014; 11: 99.

Calado M, Matoso P, Santos-Costa Q, Espirito-Santo M, Machado J, Rosado L, Antunes F, Mansinho K, Lopes MM, Maltez F, Santos-Ferreira MO, Azevedo-Pereira JM.* Coreceptor usage by HIV-1 and HIV-2 primary isolates: The relevance of CCR8 chemokine receptor as an alternative coreceptor. Virology 2010; 408: 174-182.

Azevedo-Pereira JM*, Santos-Costa Q, Mansinho K, Moniz-Pereira J. Identification and characterization of HIV-2 strains obtained from asymptomatic patients that do not use CCR5 or CXCR4 coreceptors. Virology 2003; 313: 136-146